Loteprednol Etabonate clinical trials
Also written Lotemax, Alrex, Loteprednol and KPI-121.
How each study uses Loteprednol Etabonate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 9 Mar 1998 · LOTEMAX · NDA 020583 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2014 (9)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 9 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 20
Bausch & Lomb Incorporated (16) · Kala Pharmaceuticals, Inc. (9) · Fayoum University (1) · Virginia Polytechnic Institute and State University (1) · Retina Research Institute, LLC (1) · Price Vision Group (1) · Tufts Medical Center (1) · Thomas Chester, OD (1)
Often tested with
Tested in the same studies.
Prednisolone acetate (5) · Prednisolone (5) · Dexamethasone (3) · Cyclosporine (3) · Tobramycin (3) · Cyclosporine Ophthalmic Emulsion (2) · Bromfenac (1) · Lubricant Eye Drops (1)
Studies
Open first, then newest update. How each study uses Loteprednol Etabonate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 49
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber GranulomasCompletedPhase 4Fayoum UniversityNCT07496060Written as loteprednol etabonate 1% arm 1How we know
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related PainCompletedNot applicableVirginia Polytechnic Institute and State UniversityNCT05542381Written as Loteprednol Etabonate Ophthalmic Gel [Lotemax]How we know
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour PeriodCompletedPhase 4Retina Research Institute, LLCNCT07090044Written as Loteprednol Etabonate 0.38% Ophthalmic Gel/JellyHow we know
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant RejectionCompletedPhase 4Price Vision GroupNCT05136443Written as loteprednol etabonate 0.25% ophthalmic suspensionHow we know
- The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DEDCompletedPhase 4Tufts Medical CenterNCT02120079Written as LotemaxHow we know
- Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or LotemaxCompletedPhase 4Thomas Chester, ODNCT04555694Written as Loteprednol EtabonateHow we know
- Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis TrialCompletedPhase 1Second Affiliated Hospital of Nanchang UniversityNCT05353101Written as Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%How we know
- Loteprednol vs. Prednisolone and FluorometholoneCompletedPhase 4University of UtahNCT03123614Written as Loteprednol Etabonate 0.5% Oph GelHow we know
- Safety and Efficacy of KPI-121 in Subjects With DEDCompletedPhase 3Kala Pharmaceuticals, Inc.NCT03616899Written as KPI-121 Ophthalmic SuspensionHow we know
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseCompletedPhase 3Kala Pharmaceuticals, Inc.NCT02813265Written as KPI-121 0.25% Ophthalmic SuspensionHow we know
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical InflammationCompletedPhase 3Kala Pharmaceuticals, Inc.NCT02163824Written as KPI-121 0.25%How we know
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland DiseaseCompletedPhase 2Kala Pharmaceuticals, Inc.NCT02218489Written as KPI-121How we know
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseCompletedPhase 2Kala Pharmaceuticals, Inc.NCT02188160Written as KPI-121How we know
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye DiseaseCompletedPhase 3Kala Pharmaceuticals, Inc.NCT02819284Written as KPI-121 0.25% Ophthalmic SuspensionHow we know
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and PainCompletedPhase 3Kala Pharmaceuticals, Inc.NCT02793817Written as KPI-121 1% Ophthalmic Suspension dosed BIDHow we know
- Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular EdemaCompletedNot applicableKala Pharmaceuticals, Inc.NCT02245516Written as KPI-121 0.25% Ophthalmic SuspensionHow we know
- KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in ChildrenTerminatedPhase 3Kala Pharmaceuticals, Inc.NCT03596723Written as KPI-121 1%How we know
- Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT01996839Written as Loteprednol Etabonate Gel (BID)How we know
- Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryCompletedPhase 3Bausch & Lomb IncorporatedNCT02208297Written as Loteprednol Etabonate Gel (BID)How we know
- Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) ModelCompletedPhase 4ORA, Inc.NCT00689078Written as Loteprednol Etabonate 0.2%How we know
See all 49 studies that test Loteprednol Etabonate →
As the comparator · 3 — what is tested is compared with Loteprednol Etabonate
- Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye DiseaseNot yet recruitingPhase 2Instituto de Oftalmología Fundación Conde de ValencianaNCT07671222Written as LoteprednolHow we know
- Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With KeratoconusCompletedEarly Phase 1Illinois College of OptometryNCT04418999Written as Loteprednol Etabonate 0.38% Ophthalmic Gel/JellyHow we know
- DEXTENZA Therapy for Treatment of Allergic ConjunctivitisCompletedPhase 4Clinical Research Center of FloridaNCT04708821Written as 0.2% loteprednol etabonate ophthalmic suspensionHow we know
Codes
What other systems call Loteprednol Etabonate · ClinicalTrials.gg INT006611
- MeSH (NLM) D000069559Loteprednol EtabonateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) YEH1EZ96K6LOTEPREDNOL ETABONATEConfirmed FDA, NLM, Wikidata
- RxNorm 52177Confirmed FDA, Wikidata
- Wikidata Q3837481loteprednol etabonateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47589Loteprednol EtabonateOne source FDA
- DrugBank DB14596One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069559 | Loteprednol Etabonate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | YEH1EZ96K6 | LOTEPREDNOL ETABONATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 52177 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3837481 | loteprednol etabonate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47589 | Loteprednol Etabonate | One source FDA |
| DrugBank | DB14596 | — | One source Wikidata |
Also registered as loteprednol (UNII Z8CBU6KR16 · RxNorm 237027).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.